Advanced Biomedical Technologies Inc. Announces Chinese CFDA Approval of Polymer Fixation Screws

- April 20th, 2018

Advanced Biomedical Technologies (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, announced today that it has received approval from the China Food and Drug Administration for its polymer orthopaedic internal fixation screws. As quoted in the press release: Company CEO Ms Hui Wang said, “Today is a momentous day for our company and … Continued

Advanced Biomedical Technologies (OTCQB:ABMT), a developer and manufacturer of orthopaedic internal fixation devices, announced today that it has received approval from the China Food and Drug Administration for its polymer orthopaedic internal fixation screws.

As quoted in the press release:

Company CEO Ms Hui Wang said, “Today is a momentous day for our company and biomaterial technologies as our orthopaedic internal fixation screws, based on our unique innovative composite material, gain approval from the CFDA. The revolutionary composite material developed by our company is the only biomaterial of its kind in the current market of human internal fixation devices. It consists of PA6-P(MMA-CO-NVP)-HA and is distinctively fiber-reinforced. The CFDA approval presents our company with great clinical and financial potential, and advances our mission to provide innovative products to patients that address the full continuum of orthopaedic care. The signification of this regulatory approval also means that we can bring a series of products based on the same PA biomaterial to the market much quicker. Our series of products include Binding Wires, Micromodule Screws & Plates, Maxillofacial & Craniofacial Plates and Rib Pins. We are working closely with medical institutions and the CFDA to expedite future clinical programs.”

“Polymer PA is the first of its kind among all polymer-based implantations and has no competitors due to the sophisticated manufacturing technologies and technique needed for its production. Not only is it biologically stable and easily accepted by the human body, it is also very versatile and therefore has a great market potential. This is an astounding accomplishment for our company and an imperative progression in the field of orthopaedic research and treatment” Ms Hui Wang added.

Click here to read the full press release.

Read our new 2019 medical device report today

 

 

Including: 3+ stocks to watch as well as valuable market data   Get My Free Report Click here to download for free

Leave a Reply

Your email address will not be published. Required fields are marked *